Starsource Multitrade Limited has fulfilled its quarterly regulatory obligations by submitting a confirmation certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The company, formerly known as Chemo Pharma Laboratories Limited, filed the mandatory certificate with the Bombay Stock Exchange on April 06, 2026.

Regulatory Compliance Details

The submission pertains to Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. This regulation requires companies to confirm their compliance with dematerialisation processes and related requirements on a quarterly basis.

Certificate Issuance and Confirmation

The confirmation certificate was issued by M/s. Purva Sharegistry (India) Private Limited, which serves as the company's Registrar and Share Transfer Agent (RTA). Purva Sharegistry holds SEBI registration number INR000001112 as a Category 1 Registrar for IPO and Share Transfer services.

The RTA confirmed that securities received from depository participants for dematerialisation during the quarter ended March 2026 were properly processed and confirmed to the depositories. The certificate validates that all security certificates received for dematerialisation were appropriately handled, with proper verification, mutilation, and cancellation procedures followed by the depository participants.

Corporate Leadership

The submission was signed by Ruchit Mehta, who serves as Managing Director and Chief Executive Officer of star source multi trade . Mehta holds Director Identification Number (DIN) 08810586 and executed the filing on behalf of the company.

Compliance Confirmation

Purva Sharegistry's compliance officer, Ms. Deepali Gaonkar, certified that the company maintained proper records and followed prescribed timelines for all dematerialisation processes. The confirmation ensures that the names of depositories were appropriately substituted in the register of members as registered owners within the required timeframes.

This quarterly submission represents part of the ongoing regulatory compliance framework that listed companies must maintain to ensure transparency and proper handling of securities in the dematerialised form.

Star source multi trade Limited has issued a formal clarification to the Bombay Stock Exchange regarding recent price movements in its shares. The company, formerly known as Chemo Pharma Laboratories Limited, submitted its response on April 01, 2026, addressing BSE's inquiry about share price fluctuations.

Company's Official Response

In its communication to BSE, Starsource Multitrade Limited clarified that it has consistently informed the exchange of all events and information impacting the company's operations and performance. The company emphasized its adherence to disclosure requirements under applicable regulations.

Regulatory Compliance Statement

The company stated that all price-sensitive information has been disclosed as required under Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. Management attributed the share price movement to market forces rather than any undisclosed corporate developments.

Management's Position

Ruchit Mehta, Managing Director and Chief Executive Officer, signed the response digitally. The company reiterated its commitment to maintaining transparency and keeping the stock exchange informed of any material events as and when they occur. The management emphasized that the price movement is purely market-driven and not related to any undisclosed information.

Ongoing Compliance Commitment

Starsource Multitrade Limited reaffirmed its adherence to SEBI (LODR) Regulations, 2015, particularly Regulation 30 requirements. The company assured BSE that it will continue to provide timely disclosure of all material information and events that could impact investor decisions or share price movements.